<p>Absci Corporation (NASDAQ:ABSI - 获取免费报告) 的股价在周四下跌了 9.1%。该股最低交易价格为 3.55 美元，最后交易价格为 3.6550 美元。在交易过程中，约有 2,396,006 股易手，较平均每日交易量 3,221,323 股下降了 26%。该股此前收盘价为 4.02 美元。</p>
<h2>分析师评级变动</h2>
<ul>
<li>Absci 可能成为 AI 生物科技的未来的 2 个理由，以及 1 个风险</li>
</ul>
<p>ABSI 曾受到多份分析师报告的关注。Weiss Ratings 在 10 月 8 日的报告中重申了对 Absci 股票的 &#34;卖出 (d-)&#34; 评级。摩根士丹利将 Absci 的评级从 &#34;超配&#34; 下调至 &#34;持平&#34;，并设定了 4.32 美元的目标价。HC Wainwright 在 12 月 17 日的报告中将 Absci 的目标价从 7.00 美元上调至 8.00 美元，并给予该公司 &#34;买入&#34; 评级。摩根大通在 10 月 2 日的研究报告中开始覆盖 Absci 股票，给予该公司 &#34;超配&#34; 评级。最后，Needham &amp; Company LLC 在 12 月 12 日的报告中重申了 &#34;买入&#34; 评级，并对 Absci 股票设定了 7.00 美元的目标价。五位股票研究分析师给予该股 &#34;买入&#34; 评级，一位给予 &#34;持有&#34; 评级，一位给予 &#34;卖出&#34; 评级。根据 MarketBeat 的数据，Absci 目前的平均评级为 &#34;适度买入&#34;，平均目标价为 7.66 美元。</p>
<p><strong>查看我们最新的 Absci 股票报告</strong></p>
<h2>Absci 股票表现</h2>
<ul>
<li>目前哪个医疗保健股票是最佳买入？</li>
</ul>
<p>该股的 50 日移动平均线为 3.44 美元，200 日移动平均线为 3.20 美元。该股市值为 5.5111 亿美元，市盈率为-4.08，贝塔值为 2.11。</p>
<p>Absci (NASDAQ:ABSI - 获取免费报告) 最近在 11 月 12 日公布了季度财报。公司报告每股收益 (EPS) 为（0.20）美元，低于市场共识预期的（0.19）美元，差距为（0.01）美元。该季度的营业收入为 38 万美元，而分析师预期为 158 万美元。Absci 的股本回报率为-60.19%，净利润率为-4,071.19%。分析师预计 Absci Corporation 本财年将发布-0.89 的每股收益。</p>
<h2>对 Absci 的对冲基金看法</h2>
<p>一些机构投资者最近对 ABSI 的持仓进行了调整。Quarry LP 在第三季度购买了 Absci 的新头寸，价值约 26,000 美元。Scientech Research LLC 在第三季度获得了 Absci 的新股份，价值 31,000 美元。HB Wealth Management LLC 在第三季度购买了 Absci 的新头寸，价值 31,000 美元。Principal Financial Group Inc. 在第三季度购买了 Absci 的新头寸，价值 31,000 美元。最后，Stratos Wealth Partners LTD. 在第三季度获得了 Absci 的新头寸，价值 32,000 美元。52.05% 的股票目前由机构投资者持有。</p>
<h2>关于 Absci</h2>
<p>(获取免费报告)</p>
<p>Absci Corporation NASDAQ: ABSI 是一家生物技术公司，利用机器学习、合成生物学和自动化技术加速蛋白质治疗药物的发现和开发。公司的综合药物创制平台 (IDC®) 旨在以传统生物制药发现方法无法匹敌的速度和规模识别和生产新型抗体和酶候选物。Absci 与制药和生物技术合作伙伴合作，生成、筛选和优化用于广泛治疗应用的蛋白质分子。</p>
<p>Absci 提供的核心服务是其端到端的发现引擎，结合了专有算法、高通量实验室自动化和深度学习框架。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票而非 Absci</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>崩盘前一个月</li>
<li>家族信托如何帮助保护你的财富</li>
<li>市场恐慌：特朗普刚刚对你的股票投下了一颗炸弹</li>
<li>YDES 可能是 2026 年的生物技术突破</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Absci 吗？</h2>
<p>在你考虑 Absci 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前立即购买……而 Absci 并不在名单上。</p>
<p>虽然 Absci 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

ABSI

<p>Absci Corporation（纳斯达克代码：ABSI）股价下跌 9.1%，至 3.6550 美元，交易量较平均水平下降 26%。分析师的评级意见不一，Weiss Ratings 维持 “卖出” 评级，摩根士丹利下调至 “持平”。HC Wainwright 将其目标价上调至 8.00 美元，而 Needham 重申 “买入” 评级，目标价为 7.00 美元。Absci 报告的季度每股收益为（0.20 美元），未能达到预期，市值为 5.5111 亿美元。机构投资者持有 52.05% 的股份。该股票的评级为 “适度买入”，平均目标价为 7.66 美元</p>

<p>Absci Corporation (NASDAQ:ABSI - Get Free Report)'s stock price was down 9.1% on Thursday . The stock traded as low as $3.55 and last traded at $3.6550. Approximately 2,396,006 shares changed hands during trading, a decline of 26% from the average daily volume of 3,221,323 shares. The stock had previously closed at $4.02.</p>
<div class="lb-trans"><p>Absci Corporation (NASDAQ:ABSI - 获取免费报告) 的股价在周四下跌了 9.1%。该股最低交易价格为 3.55 美元，最后交易价格为 3.6550 美元。在交易过程中，约有 2,396,006 股易手，较平均每日交易量 3,221,323 股下降了 26%。该股此前收盘价为 4.02 美元。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk</li>
</ul>
<div class="lb-trans"><ul>
<li>Absci 可能成为 AI 生物科技的未来的 2 个理由，以及 1 个风险</li>
</ul>
</div><p>ABSI has been the subject of a number of analyst reports. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Absci in a report on Wednesday, October 8th. Morgan Stanley cut shares of Absci from an &#34;overweight&#34; rating to an &#34;equal weight&#34; rating and set a $4.32 target price on the stock. in a report on Thursday. HC Wainwright boosted their price target on shares of Absci from $7.00 to $8.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday, December 17th. JPMorgan Chase &amp; Co. initiated coverage on shares of Absci in a research report on Thursday, October 2nd. They set an &#34;overweight&#34; rating for the company. Finally, Needham &amp; Company LLC reaffirmed a &#34;buy&#34; rating and issued a $7.00 price objective on shares of Absci in a report on Friday, December 12th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Absci currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $7.66.</p>
<div class="lb-trans"><p>ABSI 曾受到多份分析师报告的关注。Weiss Ratings 在 10 月 8 日的报告中重申了对 Absci 股票的 &#34;卖出 (d-)&#34; 评级。摩根士丹利将 Absci 的评级从 &#34;超配&#34; 下调至 &#34;持平&#34;，并设定了 4.32 美元的目标价。HC Wainwright 在 12 月 17 日的报告中将 Absci 的目标价从 7.00 美元上调至 8.00 美元，并给予该公司 &#34;买入&#34; 评级。摩根大通在 10 月 2 日的研究报告中开始覆盖 Absci 股票，给予该公司 &#34;超配&#34; 评级。最后，Needham &amp; Company LLC 在 12 月 12 日的报告中重申了 &#34;买入&#34; 评级，并对 Absci 股票设定了 7.00 美元的目标价。五位股票研究分析师给予该股 &#34;买入&#34; 评级，一位给予 &#34;持有&#34; 评级，一位给予 &#34;卖出&#34; 评级。根据 MarketBeat 的数据，Absci 目前的平均评级为 &#34;适度买入&#34;，平均目标价为 7.66 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on Absci</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Absci 股票报告</strong></p>
</div><h2>Absci Stock Performance</h2>
<div class="lb-trans"><h2>Absci 股票表现</h2>
</div><ul>
<li>Which Healthcare Stock Is the Best Buy Right Now?</li>
</ul>
<div class="lb-trans"><ul>
<li>目前哪个医疗保健股票是最佳买入？</li>
</ul>
</div><p>The stock has a 50 day moving average of $3.44 and a two-hundred day moving average of $3.20. The stock has a market cap of $551.11 million, a PE ratio of -4.08 and a beta of 2.11.</p>
<div class="lb-trans"><p>该股的 50 日移动平均线为 3.44 美元，200 日移动平均线为 3.20 美元。该股市值为 5.5111 亿美元，市盈率为-4.08，贝塔值为 2.11。</p>
</div><p>Absci (NASDAQ:ABSI - Get Free Report) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The business had revenue of $0.38 million during the quarter, compared to analysts' expectations of $1.58 million. Absci had a negative return on equity of 60.19% and a negative net margin of 4,071.19%. Analysts expect that Absci Corporation will post -0.89 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Absci (NASDAQ:ABSI - 获取免费报告) 最近在 11 月 12 日公布了季度财报。公司报告每股收益 (EPS) 为（0.20）美元，低于市场共识预期的（0.19）美元，差距为（0.01）美元。该季度的营业收入为 38 万美元，而分析师预期为 158 万美元。Absci 的股本回报率为-60.19%，净利润率为-4,071.19%。分析师预计 Absci Corporation 本财年将发布-0.89 的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Absci</h2>
<div class="lb-trans"><h2>对 Absci 的对冲基金看法</h2>
</div><p>A number of institutional investors have recently made changes to their positions in ABSI. Quarry LP bought a new position in Absci in the 3rd quarter worth approximately $26,000. Scientech Research LLC acquired a new stake in shares of Absci in the third quarter worth $31,000. HB Wealth Management LLC bought a new position in Absci during the third quarter worth $31,000. Principal Financial Group Inc. bought a new position in Absci during the third quarter worth $31,000. Finally, Stratos Wealth Partners LTD. acquired a new position in Absci during the 3rd quarter valued at $32,000. 52.05% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>一些机构投资者最近对 ABSI 的持仓进行了调整。Quarry LP 在第三季度购买了 Absci 的新头寸，价值约 26,000 美元。Scientech Research LLC 在第三季度获得了 Absci 的新股份，价值 31,000 美元。HB Wealth Management LLC 在第三季度购买了 Absci 的新头寸，价值 31,000 美元。Principal Financial Group Inc. 在第三季度购买了 Absci 的新头寸，价值 31,000 美元。最后，Stratos Wealth Partners LTD. 在第三季度获得了 Absci 的新头寸，价值 32,000 美元。52.05% 的股票目前由机构投资者持有。</p>
</div><h2>About Absci</h2>
<div class="lb-trans"><h2>关于 Absci</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Absci Corporation NASDAQ: ABSI is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company's Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.</p>
<div class="lb-trans"><p>Absci Corporation NASDAQ: ABSI 是一家生物技术公司，利用机器学习、合成生物学和自动化技术加速蛋白质治疗药物的发现和开发。公司的综合药物创制平台 (IDC®) 旨在以传统生物制药发现方法无法匹敌的速度和规模识别和生产新型抗体和酶候选物。Absci 与制药和生物技术合作伙伴合作，生成、筛选和优化用于广泛治疗应用的蛋白质分子。</p>
</div><p>The core of Absci's offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework.</p>
<div class="lb-trans"><p>Absci 提供的核心服务是其端到端的发现引擎，结合了专有算法、高通量实验室自动化和深度学习框架。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Absci</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>A month before the crash</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>Market Panic: Trump Just Dropped a Bomb on Your Stocks</li>
<li>YDES Could Be 2026's Biotech Breakthrough</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票而非 Absci</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>崩盘前一个月</li>
<li>家族信托如何帮助保护你的财富</li>
<li>市场恐慌：特朗普刚刚对你的股票投下了一颗炸弹</li>
<li>YDES 可能是 2026 年的生物技术突破</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Absci Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Absci 吗？</h2>
</div><p>Before you consider Absci, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Absci 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Absci wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前立即购买……而 Absci 并不在名单上。</p>
</div><p>While Absci currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Absci 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Absci (NASDAQ:ABSI) 股价下跌 9.1% - 以下是事件的经过